Samchundang Pharmaceutical finished trading on the 25th with a slight gain. Amid the persistently high volatility typical of biotech stocks, buyers and sellers remain tightly matched around the 170,000-won level.

In that day's session, Samchundang Pharm closed at 170,500 won, up 400 won (0.24%) from the previous trading day, with trading volume recorded at 147,508 shares.

Repeated Plunges and Rebounds... Digesting Volatility Is the Short-Term Watch Point

The recent stock price trend shows pronounced volatility. After closing at 182,800 won on the 20th, Samchundang Pharm plunged more than 7% on the 21st, falling to 168,700 won. It then rebounded on the 24th and continued its upward move through the 25th.

Earlier this month, the stock's movements were even more violent. On the 10th, it surged more than 14% in a single day as buying concentrated, but it subsequently fluctuated in the late 180,000-won range before falling back to the 170,000-won level. Accordingly, whether the company can digest the heightened volatility following the sharp rally is cited as a short-term watch point.

Key Catalyst Is 'Oral Insulin SCD0503'

One of the key drivers of Samchundang Pharm's stock price is the development of oral insulin. On the 5th, the company submitted a correction disclosure regarding a clinical trial to evaluate the relative bioavailability, biological activity, and food effects of oral insulin SCD0503 compared to subcutaneously injected insulin in patients with type 1 diabetes.

Earlier, in March of this year, expectations for the oral insulin development spread widely, sending the stock price soaring past 1 million won on a closing basis. As the stock has since corrected sharply, rather than judging its future direction based on the current price alone, investors need to continuously monitor the clinical progress and the company's official disclosures.

Business Progress and Tangible Results, Not Short-Term Swings, Are the Key Variables

Given the nature of the biotech and pharmaceutical business, Samchundang Pharm is a stock whose investment sentiment can shift rapidly depending on clinical trial progress and results, technology transfers and partnerships, and regulatory approval schedules. In particular, with numerous instances of large daily price swings recently, business progress and tangible results going forward — rather than short-term fluctuations — are expected to be the main variables determining the stock's direction.

[Stock investment carries the risk of greatly expanded price volatility depending on clinical trial results, approval schedules, technology transfer and contract progress, and market supply and demand. It is difficult to determine future gains or declines based solely on intraday or single-day price movements, and investors should comprehensively check the company's official disclosures, business progress, and financial condition. This article is not intended to recommend buying or selling any particular stock or to guarantee investment returns. This article was written with AI assistance.]